Email updates

Keep up to date with the latest news and content from Nutrition Journal and BioMed Central.

Open Access Research

Acute reduction of serum 8-iso-PGF2-alpha and advanced oxidation protein products in vivo by a polyphenol-rich beverage; a pilot clinical study with phytochemical and in vitro antioxidant characterization

Boris V Nemzer*, Liliana C Rodriguez, Linda Hammond, Robert DiSilvestro, John M Hunter and Zbigniew Pietrzkowski

Nutrition Journal 2011, 10:67  doi:10.1186/1475-2891-10-67

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email info@biomedcentral.com, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

In reference to comment entitled 'Questions'

Andrea Melendez-Acosta   (2011-07-26 11:13)  BioMed Central

The article to which this comment refers was not press released by Nutrition Journal nor BioMed Central (the journal publisher). The journal or the publisher has no connection with the website or author of the piece mentioned in the website above.

Competing interests

I am a Journal Development Manager at BioMed Central

top

Questions

Douglas Kalman   (2011-07-25 17:00)  Miami Research Associates

Thank you for posting and publishing this study.

A few questions:

1. Why utilize a IRB from Mexico when the study was apparently conducted in the United States? It appears that the study was conducted at a site in Orange County and there are plenty of California-based IRB's available for study and study conduct review and approval (i.e., Aspire IRB). Please explain.

2. Why allow such puffery as in this press release (http://www.nutraingredients-usa.com/Research/Futureceuticals-builds-science-defends-IP-for-coffee-fruit-extract/) since the product that appeared to be studied had over 10 ingredients and not just one that is promoted in this press release, this appears to water down the science and weaken the overall study.

Competing interests

I have no competing interests or conflicts of interest to declare

top

Post a comment